Details of the Drug Pharmacogenomic Perturbation Atlas

General Information of Drug (ID: DMUOK4C)

Drug Name
Lisinopril Drug Info
Synonyms
Acerbon; Acercomp; Alapril; Carace; Cipral; Cipril; Coric; Doneka; Hipril (TN); Inhibril; Inopril; LPR; Linopril; Linvas; Lipril; Lisinal; Lisinopril (INN); Lisinopril (anhydrous); Lisinopril anhydrous; Lisinoprilum; Lisinoprilum [Latin]; Lisipril; Lisoril; Lispril; Longes; Loril; Lysinopril; MK 521; MK 522; MK-521; Noperten; Novatec; Presiten; Prinil; Prinivil; Prinivil (TN); Sinopril; Sinopryl; Tensopril; Tensopril (TN); Tensyn; Tersif; Vivatec; Zestril; Zestril (TN)
Therapeutic ClassAntihypertensive Agents
Cross-matching ID
PubChem CID
5362119
ChEBI ID
CHEMBL43755
CAS Number
CAS 76547-98-3
TTD Drug ID
D07HGR
VARIDT Drug ID
DR00991
ACDINA Drug ID
D00370

Consensus Signature of Drug Pharmacogenomic Perturbation (DPP)
Term Name NES FDR q-val Tag % Leading Edge Genes
Fanconi anemia pathway 1.97 0.00e+0 36/54 (66.67%) FANCG;HES1;BRIP1;...
Cell cycle 1.81 2.95e-2 110/124 (88.71%) PLK1;CCND2;ORC1;...
Proximal tubule bicarbonate reclamation 1.81 1.97e-2 21/23 (91.3%) ATP1A2;CA2;CA4;...
Ovarian steroidogenesis 1.72 4.15e-2 41/51 (80.39%) IGF1;ALOX5;CYP1B1;...
AGE-RAGE signaling pathway in diabetic complications -1.67 4.04e-2 97/100 (97%) PLCG2;PLCB1;MAPK14;...
Ferroptosis -1.68 4.03e-2 36/41 (87.8%) GCLC;SLC39A8;PCBP2;...
Galactose metabolism -1.70 3.60e-2 26/31 (83.87%) GLB1;MGAM;PFKL;...
B cell receptor signaling pathway -1.71 3.56e-2 71/81 (87.65%) LILRA3;LILRA5;LILRA1;...
African trypanosomiasis -1.72 3.37e-2 32/37 (86.49%) PLCB1;PLCB4;IFNG;...
Lipid and atherosclerosis -1.72 3.57e-2 190/215 (88.37%) IKBKB;NFATC1;HSPA5;...
Rheumatoid arthritis -1.73 3.61e-2 78/93 (83.87%) CTSL;ATP6V0A2;ATP6V1D;...
Bacterial invasion of epithelial cells -1.74 3.86e-2 59/77 (76.62%) GAB1;ACTR3;ARPC2;...
Yersinia infection -1.74 4.13e-2 120/137 (87.59%) MAP3K7;ARHGEF12;LCP2;...
PD-L1 expression and PD-1 checkpoint pathway in cancer -1.75 3.69e-2 79/89 (88.76%) JAK1;IFNGR1;JUN;...
Apoptosis -1.75 3.76e-2 126/168 (75%) LMNB2;CTSL;LMNA;...
Glycosaminoglycan degradation -1.80 2.31e-2 19/19 (100%) HYAL3;NAGLU;GNS;...
Primary immunodeficiency -1.84 1.97e-2 33/38 (86.84%) TAP1;CD4;CD3D;...
Other glycan degradation -1.84 2.19e-2 13/18 (72.22%) MAN2B1;MANBA;GLB1;...
Shigellosis -1.87 1.76e-2 180/246 (73.17%) PFN1;PIK3C3;CDC42;...
Fluid shear stress and atherosclerosis -1.97 6.04e-3 123/139 (88.49%) CTSL;MGST2;HSP90AA1;...
Fc gamma R-mediated phagocytosis -2.03 0.00e+0 79/97 (81.44%) LYN;SPHK1;ACTR3;...
Osteoclast differentiation -2.17 0.00e+0 117/127 (92.13%) LILRA5;IRF9;NFKB2;...
NF-kappa B signaling pathway -2.18 0.00e+0 90/104 (86.54%) SYK;CFLAR;TRADD;...
Lysosome -2.18 0.00e+0 115/128 (89.84%) ABCB9;AP1B1;CTSL;...
IL-17 signaling pathway -2.30 0.00e+0 84/94 (89.36%) CEBPB;IKBKE;SRSF1;...
TNF signaling pathway -2.34 0.00e+0 103/112 (91.96%) CFLAR;TRADD;IL15;...
×

Pharmacogenomic Perturbation Across Diseases and Tissues

Bone
Ewing sarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
SK-ES-1 CVCL_0627 Homo sapiens 1.11uM - 10uM 24H
Brain
Glioma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
GI-1 CVCL_1230 Homo sapiens 1.11uM - 10uM 24H
Breast
Breast adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF7 CVCL_0031 Homo sapiens 0.01uM - 10uM 6H, 24H
MDA-MB-231 CVCL_0062 Homo sapiens 0.01uM - 10uM 24H
MDA-MB-468 CVCL_0419 Homo sapiens 1.11uM - 10uM 24H
Breast ductal carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
T-47D CVCL_0553 Homo sapiens 1.11uM - 10uM 24H
Breast epithelium
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
MCF-10A CVCL_0598 Homo sapiens 0.01uM - 10uM 24H
Cervix
Cervical adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HeLa CVCL_0030 Homo sapiens 0.01uM - 10uM 24H
Colon
Colorectal adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HT-29 CVCL_0320 Homo sapiens 0.01uM - 10uM 24H
SNU-407 CVCL_5004 Homo sapiens 1.11uM - 10uM 24H
Endometrium
Endometrial adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEC-108 CVCL_2926 Homo sapiens 1.11uM - 10uM 24H
HEC-1-A CVCL_0293 Homo sapiens 1.11uM - 10uM 24H
HEC-251 CVCL_2928 Homo sapiens 1.11uM - 10uM 24H
HEC-265 CVCL_2929 Homo sapiens 1.11uM - 10uM 24H
Hematopoietic system
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CJM CVCL_U797 Homo sapiens 1.11uM - 10uM 24H
Kidney
Normal (Immortalized)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HA1E CVCL_0284 Homo sapiens 0.01uM - 10uM 24H
Normal (Transformed)
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HEK293 CVCL_0045 Homo sapiens 0.01uM - 10uM 24H
Liver
Hepatocellular carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HuH-7 CVCL_0336 Homo sapiens 8uM 72H
JHH-5 CVCL_1320 Homo sapiens 1.11uM - 10uM 24H
Lung
Lung adenocarcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A549 CVCL_0023 Homo sapiens 0.01uM - 10uM 24H
NCI-H1573 CVCL_1483 Homo sapiens 1.11uM - 10uM 24H
NCI-H838 CVCL_1594 Homo sapiens 1.11uM - 10uM 24H
Lung squamous cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BEN CVCL_1081 Homo sapiens 1.11uM - 10uM 24H
HCC95 CVCL_1276 Homo sapiens 1.11uM - 10uM 24H
Non-small cell lung carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
NCI-H2110 CVCL_1529 Homo sapiens 1.11uM - 10uM 24H
Muscle
Rhabdomyosarcoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-204 CVCL_0134 Homo sapiens 1.11uM - 10uM 24H
Ovary
Ovarian clear cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
OVTOKO CVCL_3114 Homo sapiens 1.11uM - 10uM 24H
Pancreas
Pancreatic carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
YAPC CVCL_1791 Homo sapiens 0.01uM - 10uM 24H
Peripheral blood
Acute monocytic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
THP-1 CVCL_0006 Homo sapiens 0.01uM - 10uM 24H
T-cell acute lymphoblastic leukemia
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
Jurkat CVCL_0367 Homo sapiens 0.01uM - 10uM 24H
Prostate
Prostate carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
22Rv1 CVCL_1045 Homo sapiens 1.11uM - 10uM 24H
PC-3 CVCL_0035 Homo sapiens 0.01uM - 10uM 24H
Skin
Melanoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
A-375 CVCL_0132 Homo sapiens 0.01uM - 10uM 24H
IGR-37 CVCL_1303 Homo sapiens 1.11uM - 10uM 24H
Mel-HO CVCL_1402 Homo sapiens 1.11uM - 10uM 24H
SH-4 CVCL_1692 Homo sapiens 1.11uM - 10uM 24H
Umbilical vein
Normal
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
HUVEC-C CVCL_2959 Homo sapiens 0.01uM - 2.22uM 24H
Urinary bladder
Bladder carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
BC-3C CVCL_1079 Homo sapiens 1.11uM - 10uM 24H
Bladder transitional cell carcinoma
Cell Line Name Cellosaurus Accession Species of Origin Drug Dosage Time Point Details
CAL-29 CVCL_1109 Homo sapiens 1.11uM - 10uM 24H